Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: A donor stem cell transplant can lower the body's immune system, making it
difficult to fight off infection. Giving antibiotics, such as moxifloxacin, may help prevent
bacterial infections in patients who have recently undergone donor stem cell transplant. It
is not yet known whether moxifloxacin is more effective than a placebo in preventing
bacterial infections in patients who have recently undergone donor stem cell transplant.
PURPOSE: This randomized phase III trial is studying moxifloxacin to see how well it works
compared with a placebo in preventing bacterial infections in patients who have recently
undergone donor stem cell transplant.
Phase:
Phase 3
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination